Furthermore, the IDH mutation has also issued novel targeted therapeutic avenues, like the IDH enzymes dual inhibitor vorasidenib in IDH mutant glioma patients (double-blind phase 3 clinical trial). This evidence concerns the gene IDH1 and central nervous system cancer.